Here are the latest G-BA decisions from the G-BA meeting held on 7 Nov 2024 on the early benefit assessments of Retsevmo and Aqumeldi.
A complete database of all previous G-BA resolutions is in my membership.
- Retsevmo (selpercatinib); new indication: solid tumors, RET-Fusion+ – Additional benefit not proven
- Retsevmo (selpercatinib); new indication: thyroid carcinoma, RET-Fusion+, refractory to radioiodine, first-line or after prior systemic therapy, patients aged ≥ 12 years – Additional benefit not proven in both subgroups
- Aqumeldi (enalapril); heart failure, from birth to ≤ 17 years – Removal of decision from 15 Aug 2024